Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RGNX REGENXBIO Inc
- Stocks
- Healthcare
- NASDAQ: RGNX
Price (delayed)
$10.08
Market cap
$505.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.1
Enterprise value
$507.01M
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
Highlights
RGNX's gross profit has soared by 151% year-on-year and by 149% since the previous quarter
The company's revenue has surged by 88% QoQ and by 81% YoY
The equity has contracted by 30% YoY but it has grown by 6% from the previous quarter
The quick ratio has declined by 16% year-on-year but it has increased by 8% since the previous quarter
Key stats
What are the main financial stats of RGNX
Market
Valuations
Earnings
Shares outstanding
50.16M
Market cap
$505.62M
Enterprise value
$507.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.84
Price to sales (P/S)
3.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.24
Revenue
$156.72M
Gross profit
$124M
Operating income
-$157.36M
Net income
-$157.69M
EBIT
-$138.43M
EBITDA
-$122.44M
Free cash flow
-$86.94M
Per share
Balance sheet
Liquidity
EPS
-$3.1
EPS diluted
-$3.1
Free cash flow per share
-$1.69
Book value per share
$5.47
Revenue per share
$3.05
TBVPS
$9.56
Total assets
$490.93M
Total liabilities
$216.73M
Debt
$133.53M
Equity
$274.2M
Working capital
$206.51M
Debt to equity
0.49
Current ratio
2.93
Quick ratio
2.71
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
-78.1%
Gross margin
79.1%
Net margin
-100.6%
Operating margin
-100.4%
Return on assets
-30.8%
Return on equity
-53.3%
Return on invested capital
-29.1%
Return on capital employed
-36%
Return on sales
-88.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGNX stock price
How has the REGENXBIO stock price performed over time
Intraday
-0.49%
1 week
18.03%
1 month
-3.08%
1 year
-29.61%
YTD
30.4%
QTD
40.98%
Financial performance
How have REGENXBIO's revenue and profit performed over time
Revenue
$156.72M
Gross profit
$124M
Operating income
-$157.36M
Net income
-$157.69M
Gross margin
79.1%
Net margin
-100.6%
RGNX's gross profit has soared by 151% year-on-year and by 149% since the previous quarter
The company's revenue has surged by 88% QoQ and by 81% YoY
RGNX's operating margin has soared by 67% year-on-year and by 64% since the previous quarter
REGENXBIO's net margin has surged by 66% YoY and by 63% QoQ
Price vs fundamentals
How does RGNX's price correlate with its fundamentals
Growth
What is REGENXBIO's growth rate over time
Valuation
What is REGENXBIO stock price valuation
P/E
N/A
P/B
1.84
P/S
3.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.24
RGNX's EPS is up by 47% year-on-year and by 32% since the previous quarter
The equity has contracted by 30% YoY but it has grown by 6% from the previous quarter
RGNX's P/B is 23% above its last 4 quarters average of 1.5 but 20% below its 5-year quarterly average of 2.3
The company's revenue has surged by 88% QoQ and by 81% YoY
The price to sales (P/S) is 59% lower than the 5-year quarterly average of 8.1 and 34% lower than the last 4 quarters average of 5.0
Efficiency
How efficient is REGENXBIO business performance
RGNX's return on sales has surged by 70% year-on-year and by 66% since the previous quarter
The ROIC has grown by 29% from the previous quarter and by 28% YoY
REGENXBIO's ROA has increased by 26% from the previous quarter and by 25% YoY
The ROE is up by 25% YoY and by 24% QoQ
Dividends
What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGNX.
Financial health
How did REGENXBIO financials performed over time
RGNX's total assets is 127% greater than its total liabilities
RGNX's total assets is down by 22% year-on-year but it is up by 5% since the previous quarter
The current ratio has contracted by 18% YoY but it has grown by 9% from the previous quarter
REGENXBIO's debt is 51% lower than its equity
The equity has contracted by 30% YoY but it has grown by 6% from the previous quarter
REGENXBIO's debt has decreased by 22% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.